A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED in the Treatment of Patients With Moderate to Severe Ulcerative Colitis
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 190
- 试验地点
- 88
- 主要终点
- The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ≥ 30% or ≥ 3 points, and with a decrease in the rectal bleeding subscore of ≥ 1 or an absolute rectal bleeding sub-score of 0 or 1.
研究概览
简要总结
The purpose of this study is to determine whether COLAL-PRED is a safe and effective treatment for patients with moderate to severe ulcerative colitis.
详细描述
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-design, dose-ranging study. Eligible patients with a DAI score of 6 to 10 (inclusive), plus endoscopic evidence of moderate to severe ulcerative colitis as assessed by flexible sigmoidoscopy, unless colonoscopy is clinically indicated, and rectal bleeding will be randomized to placebo or one of four doses of COLAL-PRED (equivalent to 40, 60, 80, or 120 mg of prednisolone). The effectiveness and safety of COLAL-PRED will be evaluated at baseline, and after 2 weeks and 4 weeks of treatment. Additional follow-up measurements will take place 7 days post cessation of treatment.
The systemic absorption of COLAL-PRED will be determined by measuring blood levels of prednisolone, prednisolone sodium metasulfobenzoate (PMSBS) and metasulfobenzoate at Week 4.
Hypothalamic-pituitary-adrenocortical (HPA) axis response will be monitored by measuring morning serum cortisol levels at Baseline, Week 2, Week 4, and at follow-up visit and cortisol levels following adrenocorticotrophic hormone (ACTH) stimulation testing at Baseline and Week 4.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Females must be of non-childbearing potential evidenced by being surgically sterile, postmenopausal for at least 12 months or be using acceptable contraception methods such as contraceptive pill, or two forms of barrier contraception.
- •Disease Activity Index (DAI) Score of 6-10 (inclusive) at the Baseline Visit.
- •Previous colonoscopic and biopsy diagnosis of ulcerative colitis with negative evaluation of the ileum within 3 years of the screening visit.
- •Endoscopic evidence of moderate or severe mucosal disease as assessed by flexible sigmoidoscopy, with a minimum confirmed diagnosis of moderate ulcerative colitis.
- •The following concomitant prescription medications for ulcerative colitis are permitted if the following conditions are met:
- •Oral 5-aminosalicylic acid (5-ASA )therapy if the following 2 criteria are met:
- •Must be on a stable dose 2 weeks prior to baseline
- •Must maintain the stable dose until treatment end.
- •Azathioprine or 6-mercaptopurine or methotrexate if the 4 following criteria are met:
- •On therapy continually for at least 3 months prior to baseline.
- •And on a stable dose for at least 2 weeks prior to baseline.
- •And must maintain the stable dose until the end of study drug treatment.
排除标准
- •History of colonic or rectal surgery, excluding hemorrhoidal surgery or an appendectomy.
- •Pregnant or breast-feeding females.
- •Diagnosis of diabetes, heart failure, unstable angina, hepatic cirrhosis, kidney failure, adrenocortical insufficiency, or any other unstable medical condition.
- •Known hypersensitivity to corticosteroids
- •Use of oral 5-aminosalicylic acid (5-ASA) or oral corticosteroids during the immediate screening period.
- •Use of immunosuppressive drugs or antibiotics at any time within four weeks prior to screening.
- •Diagnosis of Crohn's disease; indeterminate colitis; microscopic colitis; ischemic, infectious (e.g., salmonella, shigella, etc.), or amebic colitis; or gonococcal proctitis; Clostridium difficile colitis.
- •History of tuberculosis or HIV
- •Clinically significant abnormal laboratory test results, unless regarded by the Investigator as related to ulcerative colitis
- •History of alcohol or drug abuse
- •Known malignancy or history of malignancy that would reduce life expectancy
- •Recent immunization with live viral vaccines
- •History of or active peptic ulcer disease or gastritis
- •Generalized infections such as systemic fungal or hepatitis B or C
- •History of steroid induced severe hypertension, steroid-induced psychosis, or any other severe steroid-related adverse reaction
研究组 & 干预措施
Group 1
干预措施: Placebo (Drug)
Group 2
干预措施: COLAL-PRED (Drug)
Group 3
干预措施: COLAL-PRED (Drug)
Group 4
干预措施: COLAL-PRED (Drug)
Group 5
干预措施: COLAL-PRED (Drug)
结局指标
主要结局
The proportion of patients with Complete Response at Week 4 defined as a decrease from baseline in the DAI score by ≥ 30% or ≥ 3 points, and with a decrease in the rectal bleeding subscore of ≥ 1 or an absolute rectal bleeding sub-score of 0 or 1.
时间窗: Week 4 of the study or at time of withdrawal
次要结局
- The proportion of patients in Clinical Remission defined as a DAI score of ≤ 2 points, with no-individual DAI sub-score > 1 at Week 4. Patients in remission by this definition will have a rectal bleeding DAI sub-score of either 0 or 1.(Week 4)